Side-by-side · Research reference

SemaglutidevsSemax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedVerified15/53 cited

BHuman-MechanisticDraft12/39 cited

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

Semax

Cognitive enhancer · Russian Pharma

200–600 mcg/doseIntranasalKaplan 2017

HumanMechanisticKaplan 2017

~30 minOnset

Intranasal · 2–3×/day during cognitive demand

01Mechanism of Action

Parameter

Semaglutide

Semax

Primary target

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

BDNF / NGF expression + monoamine modulationKaplan 2017

Pathway

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017

Downstream effect

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

—

Origin

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017

Antibody development

—

02Dosage Protocols

Parameter

Semaglutide

Semax

Standard dose (T2D, Ozempic)

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

—

Standard dose (weight, Wegovy)

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

—

Frequency

Once weekly, same day each week

2–3× per day during cognitive demand

Titration schedule

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

Human-mechanistic + Russian clinicalKaplan 2017

Duration

Indefinite for chronic indication

Discontinuation results in weight regain.

10–14 day cycles, repeated PRN

Reconstitution

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

Any time of day, with or without food

Morning + early afternoon

Half-life

~7 days (168 h)WEGOVY (semaglutide) injection 2021

Short plasma; CNS effect lasts ~3–6 hr

Standard dose

—

200–600 mcg / dose intranasalKaplan 2017

Lower / starter dose

—

100 mcg / dose

04Side Effects & Safety

Parameter

Semaglutide

Semax

GI symptoms

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

—

Injection site reaction

Mild erythema, pruritus

—

Pancreatitis risk

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

—

Hypoglycemia

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

—

Gallbladder events

Increased cholelithiasis

—

Pregnancy / OB

ContraindicatedWEGOVY (semaglutide) injection 2021

Avoid

Heart rate

Modest ↑ resting HR (~2-4 bpm)

—

Nasal irritation

—

Mild burning or congestion (transient)

Sleep disruption

—

Late-day dosing may interfere with sleep

Headache

—

Uncommon, transient

Long-term safety

—

Limited Western RCT data

Absolute Contraindications

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Semax

·Pregnancy / breastfeeding

Relative Contraindications

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

Semax

·Active psychiatric instability
·Concurrent strong stimulants

05Administration Protocol

Parameter

Semaglutide

Semax

1. Reconstitution / device

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.

3. Timing

Once weekly, same day. Day can be changed if ≥2 days separate doses.

Morning + early afternoon. Avoid evening (sleep disruption).

4. Storage

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

Refrigerate after reconstitution; light-protected.

5. Needle

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

Cycle on/off to avoid neurochemical adaptation.

06Stack Synergy

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)

Semax

+ Selank

Moderate

View Selank →

Semax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.

Semax: 200–600 mcg intranasal · morning + afternoon
Selank: 150–300 mcg intranasal · midday + early evening
Primary benefit: Cognitive enhancement + stress mitigation

Kaplan 2017 Zaderej 2014